Business
Grant of Options
Grant of Options.
About this update from Immupharma Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n 22 December\n \n \n 2022\n \n \n \n \n \n \n \n \n \n ImmuPharma PLC\n \n \n \n (\"ImmuPharma\" or the \"Company\")\n \n \n \n \n \n \n \n \n Grant of Share Options\n \n \n \n \n \n \n \n \n ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.\n \n \n \n \n \n The Remuneration Committee (comprising the Non Executive Directors) has determined to award Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows:\n \n \n \n \n \n Tim McCarthy 1,800,000 share options (exercise price £0.05)\n \n \n Tim McCarthy 1,800,000 share options (exercise price £0.11)\n \n \n Tim Franklin 1,575,000 share options (exercise price £0.05)\n \n \n Tim Franklin 1,575,000 share options (exercice price £0.11)\n \n \n \n \n \n Vesting & Performance conditions:\n \n \n \n \n \n ·\n 3 year vesting period; and\n \n \n ·\n 1st patient dosed in the next P140 (Lupuzor™) clinical trial.\n \n \n \n \n \n ENDS\n \n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n \n \n ImmuPharma PLC (\n \n \n \n www.immupharma.com\n \n \n \n )\n \n \n \n Tim McCarthy, Chief Executive Officer\n \n \n Lisa Baderoon, Head of Investor Relations\n \n \n \n \n +44 (0) 207 206 2650\n \n \n \n \n \n + 44 (0) 7721 413496\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n SPARK Advisory Partners Limited (NOMAD)\n \n \n \n Neil Baldwin\n \n \n \n \n \n \n \n \n Stanford Capital Partners (Joint Broker)\n \n \n \n Patrick Claridge, John Howes, Bob Pountney\n \n \n \n \n \n \n SI Capital (Joint Broker)\n \n \n \n Nick Emerson\n \n \n \n \n \n \n \n \n \n \n \n \n \n +44 (0)\n 203 36\n \n 8 3550\n \n \n \n \n \n \n \n \n \n +44 (0) 203 650 3650\n \n \n \n \n \n \n \n \n +44 (0) 1483 413500\n \n \n \n \...